A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity.

ABSTRACT:

Background

Obese asthmatics tend to have poorly controlled asthma, and resistance to standard asthma controller medications. The purpose of this study was to determine the efficacy of pioglitazone, an anti-diabetic medication which can alter circulating adipokines and have direct effects on asthmatic inflammation, in the treatment of asthma in obesity.

Methods

A two-center, 12-week, randomized, placebo-controlled, double-blinded trial. Treatments were randomly assigned with concealment of allocation. The primary outcome was difference in change in airway reactivity between participants assigned to pioglitazone versus placebo at 12 weeks.

Results

Twenty-three participants were randomized to treatment, 19 completed the study. Median airway reactivity, measured by PC20 t

SUBMITTER: Dixon AE 

PROVIDER: S-EPMC4661996 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature